Analysts Anticipate Amgen, Inc. (AMGN) Will Post Earnings of $3.45 Per Share

Share on StockTwits

Wall Street analysts expect that Amgen, Inc. (NASDAQ:AMGN) will announce earnings per share (EPS) of $3.45 for the current quarter, according to Zacks. Six analysts have issued estimates for Amgen’s earnings. The highest EPS estimate is $3.63 and the lowest is $3.04. Amgen posted earnings of $3.47 per share during the same quarter last year, which would suggest a negative year over year growth rate of 0.6%. The company is expected to announce its next quarterly earnings results after the market closes on Tuesday, April 30th.

On average, analysts expect that Amgen will report full-year earnings of $13.96 per share for the current year, with EPS estimates ranging from $13.30 to $14.75. For the next financial year, analysts expect that the company will post earnings of $14.62 per share, with EPS estimates ranging from $11.60 to $15.99. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Amgen.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 EPS for the quarter, beating the Zacks’ consensus estimate of $3.26 by $0.16. Amgen had a net margin of 35.35% and a return on equity of 66.74%. The company had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $5.88 billion. During the same quarter in the prior year, the company posted $2.89 EPS.

A number of analysts recently issued reports on AMGN shares. Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Monday, April 15th. Citigroup increased their target price on shares of Amgen from $204.00 to $210.00 and gave the stock a “neutral” rating in a research report on Friday, January 4th. Goldman Sachs Group reissued a “buy” rating and set a $232.00 target price on shares of Amgen in a research report on Thursday, January 17th. Oppenheimer set a $224.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Sunday, January 27th. Finally, Royal Bank of Canada reissued a “neutral” rating on shares of Amgen in a research report on Friday, February 1st. Eleven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Amgen currently has an average rating of “Hold” and a consensus price target of $209.11.

NASDAQ AMGN opened at $177.47 on Thursday. The stock has a market cap of $109.31 billion, a PE ratio of 12.32, a P/E/G ratio of 2.17 and a beta of 1.21. Amgen has a 12 month low of $165.22 and a 12 month high of $210.19. The company has a debt-to-equity ratio of 2.36, a current ratio of 2.79 and a quick ratio of 2.57.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a yield of 3.27%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is presently 40.28%.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $193.18, for a total value of $386,360.00. Following the completion of the transaction, the director now owns 15,092 shares in the company, valued at approximately $2,915,472.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders sold 6,000 shares of company stock valued at $1,144,120. 0.27% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its holdings in Amgen by 2.0% in the 4th quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock worth $8,979,621,000 after acquiring an additional 906,568 shares during the period. Oregon Public Employees Retirement Fund boosted its holdings in Amgen by 20,103.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock worth $161,000 after acquiring an additional 31,268,677 shares during the period. Northern Trust Corp boosted its holdings in Amgen by 4.7% in the 4th quarter. Northern Trust Corp now owns 9,182,050 shares of the medical research company’s stock worth $1,787,470,000 after acquiring an additional 408,675 shares during the period. Geode Capital Management LLC boosted its holdings in Amgen by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock worth $1,720,250,000 after acquiring an additional 482,760 shares during the period. Finally, Norges Bank purchased a new position in Amgen in the 4th quarter worth approximately $1,283,248,000. Hedge funds and other institutional investors own 79.18% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Recommended Story: Risk Tolerance and Your Investment Decisions

Get a free copy of the Zacks research report on Amgen (AMGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Athene’s  “Hold” Rating Reiterated at Royal Bank of Canada
Athene’s “Hold” Rating Reiterated at Royal Bank of Canada
Jefferies Financial Group Boosts Abbott Laboratories  Price Target to $98.00
Jefferies Financial Group Boosts Abbott Laboratories Price Target to $98.00
BP  Downgraded by ValuEngine to “Sell”
BP Downgraded by ValuEngine to “Sell”
Chipotle Mexican Grill  Price Target Increased to $750.00 by Analysts at Wedbush
Chipotle Mexican Grill Price Target Increased to $750.00 by Analysts at Wedbush
Novartis  Cut to Hold at Zacks Investment Research
Novartis Cut to Hold at Zacks Investment Research
AON  Price Target Raised to $197.00
AON Price Target Raised to $197.00


 
© 2006-2019 Zolmax.